Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants
A Multicenter, Randomized, Double-Masked, Controlled Study to Evaluate the Safety & Efficacy of Intravitreal Fluocinolone Acetonide (0.59 or 2.1 mg) Implant in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Eye Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or non-pregnant females at least 6 years of age who had been diagnosed and treated for recurrent, non-infectious uveitis affecting the posterior segment of one or both eyes for at least 1 year prior to the start of the study, and had 'quiet' eyes at surgery
Exclusion Criteria:
- Coexisting medical or ocular conditions that would interfere with the study results
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Fluocinolone acetonide 0.59mg
Fluocinolone acetonide ocular implant 0.59mg
|
Fluocinolone acetonide ocular implant 0.59mg
|
|
Experimental: Fluocinolone acetonide 2.1mg
Fluocinolone acetonide ocular implant 2.1mg
|
Fluocinolone acetonide ocular implant 2.1mg
|
|
No Intervention: No intervention
Fellow eye
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Recurrence of uveitis before and after implantation.
Time Frame: 34 weeks pre-implantation; 34 weeks, 1 year, 2 years and 3 years post-implantation
|
34 weeks pre-implantation; 34 weeks, 1 year, 2 years and 3 years post-implantation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Post-implantation rate of uveitis recurrence, within patient comparison of implanted vs fellow eyes.
Time Frame: 34 weeks, 1 year, 2 years and 3 years post-implantation
|
34 weeks, 1 year, 2 years and 3 years post-implantation
|
|
Post-implantation time to recurrence of uveitis within patient comparison of implanted vs fellow eyes.
Time Frame: 34 weeks, 1 year, 2 years and 3 years post-implantation
|
34 weeks, 1 year, 2 years and 3 years post-implantation
|
|
The need for adjunctive uveitis treatment for the study eye, within patient comparison (pre- versus post-implantation)
Time Frame: 34 weeks, 1 year, 2 years and 3 years post-implantation
|
34 weeks, 1 year, 2 years and 3 years post-implantation
|
|
Reduction in the area of cystoid macular edema (CME) within patient comparison of responding eyes (implant vs fellow eyes)
Time Frame: 34 weeks, 1 year, 2 years and 3 years post-implantation
|
34 weeks, 1 year, 2 years and 3 years post-implantation
|
|
Results of QOL surveys pre- versus post-implantation
Time Frame: 34 weeks, 1 year, 2 years and 3 years post-implantation
|
34 weeks, 1 year, 2 years and 3 years post-implantation
|
|
Visual acuity, within patient comparison of responding eyes (implant vs fellow eyes)
Time Frame: 34 weeks, 1 year, 2 years and 3 years post-implantation
|
34 weeks, 1 year, 2 years and 3 years post-implantation
|
|
Time to recurrence, between treatment group comparison
Time Frame: 34 weeks, 1 year, 2 years and 3 years post-implantation
|
34 weeks, 1 year, 2 years and 3 years post-implantation
|
|
Post implantation uveitis rate, between treatment group comparison
Time Frame: 34 weeks, 1 year, 2 years and 3 years post-implantation
|
34 weeks, 1 year, 2 years and 3 years post-implantation
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Thomas A Crescuillo, Bausch & Lomb Incorporated
Publications and helpful links
General Publications
- Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T; Fluocinolone Acetonide Uveitis Study Group. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006 Jun;113(6):1020-7. doi: 10.1016/j.ophtha.2006.02.021. Epub 2006 May 9.
- Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol. 2008 Sep;126(9):1191-201. doi: 10.1001/archopht.126.9.1191.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 415-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.